Eli Lilly and Company (LLY)vsQuipt Home Medical Corp (QIPT)
LLY
Eli Lilly and Company
$916.31
-2.11%
HEALTHCARE · Cap: $808.22B
QIPT
Quipt Home Medical Corp
$3.65
0.00%
HEALTHCARE · Cap: $162.30M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 24498% more annual revenue ($65.18B vs $264.97M). LLY leads profitability with a 31.7% profit margin vs -4.0%. LLY earns a higher WallStSmart Score of 80/100 (A-).
LLY
Exceptional Buy80
out of 100
Grade: A-
QIPT
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+14.0%
Fair Value
$1065.17
Current Price
$916.31
$148.86 discount
Intrinsic value data unavailable for QIPT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Revenue surging 32.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.9x book value
Smaller company, higher risk/reward
Operating margin of 1.5%
ROE of -9.3% — below average capital efficiency
Earnings declined 97.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : QIPT
The strongest argument for QIPT centers on Revenue Growth, Price/Book. Revenue growth of 32.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : QIPT
The primary concerns for QIPT are Market Cap, Operating Margin, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while QIPT is a hypergrowth play — different risk/reward profiles.
QIPT carries more volatility with a beta of 0.49 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (80/100 vs 40/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Exceptional Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Quipt Home Medical Corp
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Quipt Home Medical Corp. The company is headquartered in Wilder, Kentucky.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?